Women continue to drop out of an FDA-required long-term study, with nearly 16% of all Essure patients having the devices surgically removed, even though it was designed to be a permanent form of birth control
Nearly half of participants have discontinued the Essure birth control implant post-marketing study, causing massive losses in follow-up data, the FDA warns.
Abdominal pain and bleeding were the two most frequently reported Essure adverse events, according to the FDA.
The analysis comes from postmarketing surveillance data on Essure recipients, which was required by the FDA after Bayer pulled the birth control implant from the market in 2018.
